A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGM-HF
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Nov 2017 Results (n=1935) assessing changes in growth differentiation factor 15 (GDF-15) and the prognostic value of baseline GDF-15 in patients with heart failure with reduced ejection fraction, presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 14 Nov 2017 Results of pooled data from two trial (PARADIGM-HF and ATMOSPHERE), were published in the Journal of the American College of Cardiology.
    • 12 Oct 2017 Results assessing potential mortality reduction with optimal usage of sacubitril/valsartan therapy for the treatment of heart failure in mexico, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top